In 2018 alone, an estimated 20,000 new acute myeloid leukemia (AML) patients 11 were diagnosed, in the United States, and over 10,000 of them are expected to 12 die from the disease. AML is primarily diagnosed among the elderly (median 68 13 years old at diagnosis). Prognoses have significantly improved for younger 14 patients, but in patients older than 60 years old as much as 70% of patients will 15 die within a year of diagnosis. In this study, we conducted stratified 16 computational meta-analysis of 2,213 acute myeloid leukemia patients compared 17 to 548 healthy individuals, using curated publicly available data. We carried out 18 analysis of variance of normalized batch corrected data, including considerations 19 for disease, age, tissue and sex. We identified 974 differentially expressed probe 20 sets and 4 significant pathways associated with AML. Additionally, we identified 21 70 sex-and 375 age-related probe set expression signatures relevant to AML. 22
INTRODUCTION 31
Acute myeloid leukemia (AML) is a heterogeneous malignant disease of the 32 hematopoietic system myeloid cell lineage. AML is best characterized by the 33 terminal differentiation in normal blood cells and excessive production and 34 release of cells at various stages of incomplete maturation (leukemia cells). As a 35 result of this faster than normal and uncontrolled growth of leukemia cells, 36 healthy myeloid precursors involved in hematopoiesis are suppressed, and 37 ultimately, can soar to death within months from diagnosis if untreated 1,2 . AML 38 accounts for 70% of myeloid leukemia and nearly 80% of acute leukemia cases, 39 making it the most common form of both myeloid and acute leukemia 2,3 . The 40 number of new AML cases is increasing each year -in 2018 alone, there have 41 been an estimated about 20,000 new diagnosed AML patients, over 10,000 of 42 them will die from the disease 4 . 43
44
According to the 2016 World Health Organization (WHO) newly revised myeloid 45 neoplasms and acute leukemia classification system 5 , AML prognosis criteria for 46 therapeutic strategy for younger patients 13, 14 . However, in patients older than 60 70 years old, prognoses remain grim and therapeutic strategy has been nearly the 71 same for more than 30 years 2,6,13-15 . Approximately 70% of AML patients 65 72 years of age or older die within a year following diagnosis 16 . While it is apparent 73 that the nature of AML changes with age, still little is known about the extent of 74 these associations and how they vary with patient's age 14, 17, 18 . Taking into 75 consideration age considerations in the identification of changes in AML global 76 gene expression can lead to improved early diagnosis and improvement in 77 treatment approaches for elderly patients. Further complicating, AML has 78 multiple driver mutations and competing clones that evolve over time, making it a 79 very dynamic disease 19,20 80 81 Multiple gene expression analyses of AML have been carried out, 25 of which 82 these have been systematically compared by Miller and Stamatoyannopoulos 21 , 83 who analyzed information on 4918 genes, and identified 25 genes reported 84 across multiple, with potential prognostic features. In this study, we performed 85 comprehensive gene expression meta-analysis of 2213 acute myeloid leukemia 86 patients and 548 healthy subjects using 34 publicly available gene expression 87 microarray datasets (following strict inclusion criteria) to identify disease, sex-88 and age-related gene expression changes associated with AML. We identified 89 sex-and age-related gene expression signatures that show similar alteration in 90 gene expression levels and associated signaling pathways in AML and have 91 used our results (gene sets) to predict AML or healthy status. We believe that our 92 results may lead to improved AML early detection and diagnostic testing with 93 target genes, which collectively can potentially serve as sex-and age-dependent 94 biomarkers for AML prognosis compared to healthy, as well as the identification 95
of new treatment targets with mechanisms of action different from those used in 96 conventional chemotherapy 97 98 RESULTS 99
Data curation and gene expression preprocessing. 100
We searched the Gene Expression Omnibus (GEO) public repository, based on 101 our systematic workflow and inclusion criteria, Fig. 1a -b. Overall, 2,132 datasets 102 were screened, 643 selected (577 were excluded as non-Affymetrix, various 103 platform arrays). From the 66 remaining, 34 studies were excluded due to lack of 104 metadata, non-peripheral blood and non-bone marrow tissues, cell line or cell-105 type specific, treated subjects). After this curation we obtained 34 age-annotated 106 gene expression datasets from 32 different studies covering 2,213 AML patients 107 and 548 healthy individuals. The sets were re-analyzed, starting from raw data, 108 to perform a gene expression analysis of variance and functional pathway 109 enrichment analysis (see online Methods). 
Batch correction 133
Our pre-processed data, AML and healthy, were processed using a "dataset-134 wise" batch effect correction approach. The datasets used in this study did not 135 include within-study healthy controls, which would limit analysis of variance, and 136 particularly the ability to separate biological from batch effects. To address this, 137
we implemented an iterative batch effect correction approach, essentially 138 employing a weight-based method for correcting batch effects. Assuming the 139 batch effects due to each data set is a function of the number of samples in the 140 data set (weight), normalizing sets of unevenly sized datasets may lead to 141 unbalanced batch correction. We used 5 additional datasets as a reference set, 142 which we refer to as "covariate" hereafter. Each of the covariate reference 143 datasets included within study healthy controls. All 5 datasets together consisted 144 of a total 613 arrays (455 AML and 158 healthy) ( Table 2) , and pre-processed 145 exactly as our curated data sets. These were used together with each of the 146 remaining datasets to batch correct each dataset with respect the covariate 147 reference using ComBat 23 . After this dataset-wise correction, the 5 covariate 148 reference datasets were removed, and our expression data were clustered using 149 principal component analysis (PCA) to visually examine the effect of covariate 150 reference datasets on distributing the batch weight during batch correction. The 151 batch effect correction results were then compared to clustering results prior to 152 batch effect correction ( Supplementary Fig. 1 terms) can be found as Supplementary Table S3 online. Further analysis of gene expression and pathways enrichment were conducted in 212 order to characterize sex-and age-specific gene expression changes in AML 213 patients compared to healthy individuals, (i) Analysis 2a: "Sex-relevance 214 differential gene expression meta-analysis and associated signaling 215 pathways in AML", and (ii) Analysis 2b: "Age-dependent differential gene 216 expression meta-analysis and associated signaling pathways in AML". We 217 used the same filtering criteria in both analyses as those used in analysis 1 for 218 significant DEPS and signaling pathways between AML patients and healthy 219 controls. In addition, DEPS were regarded as statistically significantly (up-or 220 down-regulated) for each factor, sex and age, if they displayed Bonferroni 221 adjusted p-value from Tukey's HSD < 2.2x10 -7 (=0.01/44,754 probe sets tested). 222 223 Analysis 2a. Sex-relevance differential gene expression meta-analysis and 224 associated signaling pathways in AML. 225
Gene expression meta-analysis was also used to identify DEPS that show sex 226 differences between male AML patients as compared to female AML patients. 227 266 DEPS were regarded statistically significant (p-value < 2.2x10 -7 ). A list of all 228 266 DEPS (including whether higher in either males or females, gene title and 229 symbol, male-female mean difference, and Bonferroni corrected p-value) can be 230 found as Supplementary Table S3 online. 70 DEPS were found to overlap 231 between analysis 1 (AML disease state) and analysis 2 (Sex-relevance in AML). 232 Figure 3a shows these 70 DEPS with gene symbol annotations, and their mean 233 difference values in the heatmap, which displays differences in significance for a 234 common DEPS in both analyses 1 and 2. Figure 3b For enrichment analysis, we searched for common intersections in KEGG 241 pathways and GO terms between the sex meta-analysis and the 974 DE probe 242 sets from disease state in AML meta-analysis. Sex-relevant DEPS were found in 243 3 different signaling pathways, including, genes higher expressed in males FLT3 244 and CD34 in Hematopoietic cell lineage, FLT3 in Transcriptional misregulation in 245 cancer 1, and PMAIP1 in p53 signaling pathway 1, and MS4A1 was higher in 246 females and found in Hematopoietic cell lineage pathway (Table 3 ). Figure 3d  247 shows GO analysis results, where 15 overrepresented biological GO terms were 248 overlapped, including terms for extracellular space, immune response, protein 249 binding, spindle, and midbody. The entire list of our enrichment analysis 250 (statistically significant KEGG and GO terms) can be found as Supplementary  251   Table S4 . 252 253 Analysis 2b. Age-dependent differential gene expression meta-analysis and 254 associated signaling pathways in AML. 255
The subjects were binned in 8 age-groups: 0-19, 20-29, 30-39, 40-49, 50-59, 60-256 69, 70-79, and 80-100 years old. From this meta-analysis, 1395 unique probe 257 sets across all age-groups were identified as statistically significant (Bonferroni 258 adjusted p-value < 2.2x10 -7 ) ( Supplementary Table S5 ). From these 375 unique 259 DEPS (372 unique gene symbols) were found to overlap with the 974 DEPS 260 probe sets from our AML disease state meta-analysis, accounting for an overall 261 1400 binary comparisons between the multiple age groups deemed statistically 262 significant, based on Tukey HSD tests between age-group pairs. The entire list of 263 1400 identified pairwise differences between age groups and associated probe 264 set/gene information can be found as Supplementary Table S6 To investigate further the progression with age, pairwise correlations between 273 age-groups were computed. The 0-19 age-group was used as a common 274 comparison reference with respect to other groups. Using this 0-19 group as a 275 baseline, Figure 4d shows the mean difference of 25 DEPS with respect to the 0-276 19 baseline across all other groups. The mean difference values between AML 277 and healthy are shown in the right-most column of Fig. 4a In the present study, we aimed to establish, disease sex-linked and age-289 dependent biomarkers from genes with similar changes in gene expression 290 levels and associated signaling pathways relevant to AML. Utilizing microarray 291 gene expression data and combined with various machine learning models, 292 respectively, our biomarkers were indicative of prognostic signature for AML 293 prediction compared to healthy with 90+% achieved accuracy. We re-analyzed 294 data aggregated from our curation of 34 publicly available microarray gene 295 expression datasets covering 2213 AML patients and 548 healthy individuals to 296 identify changes in AML gene expression associated with disease state (AML 297 compared to healthy), sex-linked (male compared to female), and age-dependent 298 (across age-groups compared to baseline). 299
We performed 3 differential probe set (gene) expression and gene enrichment 300 analyses, as discussed below. We note here that our study identified multiple 301 potentially significant DEPS, with age and sex related differences associated with 302 AML. While our findings may generate further hypothesis-driven investigations, 303
we need to also identify the study's limitations: primarily the analysis of AML and 304 healthy subjects involved bone-marrow and blood samples respectively in each 305 disease group. We tried to account for this utilizing tissue as an effect in our 306 linear model, and including multiple interactions. Other limitations include an 307 unbalanced AML/healthy ratio, as well as the lack of in-study healthy controls. To 308 address these we attempted to account for batch effects using a dataset-wise 309 iterative batch correction transformation, as discussed in the methods. Finally, 310
we also included binary interactions between the factors in the analysis to 311 account for interaction-related confounding effects. Among these 6 genes are known to be involved in AML functional pathways, 320
including 4 up-regulated, JUP, CCNA1, FLT3, PIK3R1, and 2 down-regulated, 321 CD14, CEBPE. The top 10 up-and down-regulated genes from this analysis are 322 listed in Table 2 with their respected Tukey's HSD mean difference and 323
Bonferroni p-adjusted values. As shown in Figure 2b Stamatoyannopoulos that were reported in at least 8 studies 21 , namely HOXA10, 363 CD34, MEIS1,VCAN, RBPMS and MN1. In terms of the genes reported in the 364 same study for poor progression we also consistently identified as upregulated 365 HOXA10, RBPMS, CD34, GNAI1, CLIP2, DAPK1, GUCY1A3, ANGPT1 and 366 FLT3, and as downregulated UGCG. While these are known markers, with 367 consistent expression differences, our additional results need to be investigated 368 further and experimentally validated, including mechanistic considerations. 369 370 ii) Analysis 2a: Sex-dependent gene expression meta-analysis and associated 371 signaling pathways in AML compared to healthy individuals, was performed to 372 explore the relevance of patients' sex on gene expression and to identify sex-373 linked genes and associated signaling pathways in AML. A total of 266 DEPS 374 were found statistically significant in this analysis, with 70 found to overlap with 375 the DEPS from Analysis 1 (Fig 3a-b) . The top10 up-and down-regulated DE 376 genes with respect to females include (Fig. 3c) (Protein Kinase X-Linked) were as higher in females. These genes are known to 382 be sex-specific and show such differences and sex separation within the AML 383 and the healthy groups respectively (Fig. 3d ). The role of these genes as positive 384 controls in studies with AML needs to be investigated further. We also reported 385 sex and AML known genes that were statistically significant in our analysis, 386 including FLT3 and MAL. 387 388 iii) Analysis 2b: Age-dependent gene expression meta-analysis and associated 389 signaling pathways in AML compared to healthy individuals, was carried out to 390 identify common set of age-dependent genes and associated signaling pathways 391 and to explore age-dependent trends in gene expression in AML. The age-392 dependent meta-analysis in AML using ANOVA, identified 1,395 DEPS 393 (Bonferroni adjusted p-value <0.01). To identify age-related DEPS in AML we 394 overlapped the 1,395 DEPS to our findings of 974 DEPS in AML disease state 395 (Analysis 1) (Fig. 4a) , and identified an overlap of 375 DEPS (Bonferroni 396 adjusted p.value <0.01). As shown in Figure 4b , the top 10 most and least DE 397 age-associate genes in AML according to the mean difference values in seven 398 age-groups, including their corresponding values from AML disease state in 399 column "AML -healthy" for comparisons. Interestingly, CRISP3 was among the 400 down regulated genes specifically and involved in this analysis as well, 401 specifically associated with differences in younger age groups, 20 to 49 years of 402 age as compared to 0 to 19 age group. Other genes showing age-specific 403 differences included HOXA3, HOXA5 and HOXA10-HOXA9, which belong to the 404 homeobox genes (HOX) family of transcription factors, essential to embryonic 405 development and hematopoiesis, and associated with chromosomal 406 abnormalities translocation and over-expression in AML 44,45 . Also identified with 407 age-specific DE, was ORM1, which in Analysis 1 was among the top-10 most 408 under-expressed genes, and was also among the 70 DE genes in analysis 2a. 409 ORM1's direct role in AML also merits further investigation, given ORM1 410 involvement in immunosuppression and inflammation 46 . Finally, we have 411 identified 75 DEPS that show association with only one age-group, exclusively 412 from all other age-groups, suggestive of potential age-specific differential gene 413 expression signature. 414
415
In summary, our study successfully integrated multiple datasets to perform a 416 study of gene expression in AML, across multiple factors that included disease, 417 sex and age considerations, and identified interesting genes, both known and not 418 previously reported as differentially expressed in each factor. We identified 974 419 DEPS and 4 associated significant pathways involved in AML, and 70 sex-and 420 375 age-related DE signatures. Using the 974 DEPS, a KNN model allowed AML 421 with 91.7% accuracy. We hope that these findings may provide additional 422 relevant targets for further experimental mechanistic studies, and to help identify 423 new markers and therapeutic targets for AML. 424
425

METHODS 426
The generalized workflow consisted of five main steps: i) Curation of microarray 427 gene expression data, ii) Preprocessing of raw data files followed by batch effect 428 correction, iii) Predictions of missing annotation data using supervised machine 429 learning, iv) Differential gene expression analysis, and v) Gene enrichment for 430 pathway analysis that includes gene annotation, and finally gene expression-431 based prediction of AML (Fig. 1a) . 432 433
Gene expression data curation and screening criteria. 434
Datasets used in this study were selected from the GEO public repository, 435 maintained by the National Center for Biotechnology Information (NCBI) 47 436 (https://www.ncbi.nlm.nih.gov/geo/). To facilitate speed of search and keep up-to-437 date with possible new and relevant datasets, as soon as they were released, a 438
Python script was used that utilized functions from the Entrez Utilities from 439 Biopython 48 . We used the script to navigate the GEO records, and download 440 microarray gene expression datasets up to 10/18. We additionally utilized Python 441 packages, including Pandas, NumPy, and Matplotlib for data structure, numerical 442 computing for data processing, and data visualization respectively. We used 443 strict inclusion criteria to maintain consistency in each dataset selection, screen 444 for availability of both raw and meta-data annotation files provided, human 445 samples used from untreated subjects, and that the sample source was from 446 either bone marrow (BM) and/or peripheral blood (PB). Array platform was 447 restricted to Affymetrix, which was found to have the most available data, and to 448 avoid cross-platform normalization issues. Inclusion criteria and the data curation 449 workflow are illustrated in Fig. 1 a- preprocessing. For each dataset used in our analysis, raw microarray CEL files 471 were downloaded from GEO, metadata was reviewed, and the data was 472 manually curated to guarantee that and each array, which corresponded to either 473 an AML patient or healthy individual, was verified and correctly annotated for 474 sample source (BM or PB), platform technology used, age, sex, and disease 475 state (AML or healthy). Raw CEL files from individual datasets were individually 476 pre-processed using the RMA (Robust Multi-Array Average) algorithm [54] [55] [56] . were not annotated for sex, while 737 arrays (all AML patients) were missing 492 sample source information. Without these metadata, we would have to discard 493 the data, which in turn would limit the statistical power for the study, and our 494 ability to correct for biases stemming from individual datasets 22 . To address this, 495
we used supervised machine learning classifiers to predict metadata. For all 496 prediction, we used ClassificaIO 37 , a machine learning for classification user 497 interface, which we recently developed, to carry out the machine learning 498 classification analyses utilizing the sklearn package in Python 57 499 500
To predict sex pre-processed data sets, 1956 arrays (including both healthy and 501 AML), that include 44,754 probe sets and their annotated sex information were 502 used to train logistic regression (LR) classification models, and to predict 805 sex 503 annotations. Additionally, 2024 arrays were used to train for sample source, and 504 the prediction was performed on 737 arrays. training and testing are presented in Supplementary Table S1 online, and results 518 in Supplementary files 1 and 2. To account for training overfitting, we used 10-519 fold cross-validation on all 1,956 gene expression data arrays for training and 520 validation. 521 522 Dataset-wise correction approach for batch effects correction. 523
Batch correction was done using a dataset-wise correction. Here we refer to the 524 term "dataset-wise correction," to indicate performing batch correction iteratively 525 on one dataset at a time, against a reference set of datasets chosen to account 526 for variability. We used this approach to account for the lack within-study healthy 527 controls in the curated gene expression datasets. To address this issue, we used 528 5 additional datasets the included within-study controls, GEO accessions: 529 GSE107968, GSE68172 58 , GSE17054 59 , GSE33223 60 , and GSE15061 61 ( Table  530 1B). We refer to the latter datasets hereafter as "covariate" reference datasets, 531 as they were as the reference datasets in the batch correction. Our approach 532 aimed to balance/distribute the weight of batch effects exerted by each dataset, 533 as this is dependent on the number of observations within a given dataset. 534
Combined, the covariate reference datasets included 613 total arrays, totaling 535 455 AML and 158 healthy controls. We used ComBat 23 to correct for study batch 536 effects, as its empirical Bayes-based algorithm uses both scale and mean center 537 based methods, providing an appropriate algorithm 23 . Covariate reference 538 datasets were treated as the covariate for batch during batch correction, to 539 improve performance in correcting for batch effects rather than biological 540 variation. After batch correction, we used principal component analysis (PCA), 541 visualizing components in both 2 and 3 dimensions, to compare the clustering 542 results for corrections. Covariate reference datasets were removed after the 543 batch correction step and were not part of our downstream meta-analysis. 544
( Supplementary Fig. S1 ). 545 546
Gene expression meta-analysis. 547
After batch correction step, we performed gene expression meta-analysis for 548 differential expression on the merged datasets (34 data sets, 16 AML and 18 549 healthy), where the expression values for all 44,754 common probe sets were 550 aggregated. The effects of patients' age, sex, and sample source, including their 551 pairwise interactions were investigated using an analysis of variance (ANOVA) 8,62 552
. For each gene i, where i=[1,…44,754], the gene expression probe set Yi was 553 modeled computationally as a linear model: 554
Yi ~ (a + s + d + t) + (a:s + a:d + a:t) + (s:d + s:t) + (d:t) + ε, 555
where d is the disease state (AML or healthy), a is age (between 0 to 100 years), 556 s is sex (female or male), t is sample source (BM or PB), and ε is a random error 557 term. We note that the model includes sample source and its interactions to 558 address comparisons involving different tissues in AML and healthy subjects (BM 559 or PB respectively). 560 561 From the ANOVA analysis, genes were deemed to be disease state statistically 562 significant (differentially expressed) if they displayed ANOVA Bonferroni-adjusted 563 p-value < 0.01. Post-hoc analysis for significant genes was conducted for 564 comparisons (between groups) using Tukey's Honestly Significant Difference 565 (HSD) tests. Additionally, we performed a quantile-based effect filter, were genes 566 were deemed to show biological effects in our analysis if they displayed mean 567 difference values in the <5% and/or > 95% quantiles of the mean difference 568 The datasets generated in the study, supplementary data, tables, figures and 599 files are available online at http://doi.org/10.5281/zenodo.1492796 600
Datasets re-analyzed in the study are publicly available on the Gene Expression 601
Omnibus repository, at https://www.ncbi.nlm.nih.gov/geo/ under accessions 602 summarized in Table 1 . Table 4 : Enrichment analysis was done using 974 DEPS overlapped with age-specific analysis * up and down regulated genes displayed
